Overview of the Current Pathophysiology of Fatigue in Multiple Sclerosis, Its Diagnosis and Treatment Options – Review Article

References

• Khan F, Amatya B, Galea M. Management of fatigue in persons with multiple sclerosis. Front Neurol. 2014;5. doi:10.3389/fneur.2014.00177
   Web of Science ®Google Scholar
• Brownlee WJ, Hardy TA, Fazekas F, Miller DH. Diagnosis of multiple sclerosis: progress and challenges. Lancet. 2017;389(10076):1336–1346. doi:10.1016/S0140-6736(16)30959-X
   PubMed Web of Science ®Google Scholar
• Ayache SS, Serratrice N, Abi Lahoud GN, Chalah MA. Fatigue in multiple sclerosis: a review of the exploratory and therapeutic potential of non-invasive brain stimulation. Front Neurol. 2022;13:813965. doi:10.3389/fneur.2022.813965
   PubMed Web of Science ®Google Scholar
• Nagaraj K, Taly AB, Gupta A, Prasad C, Christopher R. Prevalence of fatigue in patients with multiple sclerosis and its effect on the quality of life. J Neurosci Rural Pract. 2013;04(03):278–282. doi:10.4103/0976-3147.118774
   Google Scholar
• Oliva Ramirez A, Keenan A, Kalau O, Worthington E, Cohen L, Singh S. Prevalence and burden of multiple sclerosis-related fatigue: a systematic literature review. BMC Neurol. 2021;21(1):468. doi:10.1186/s12883-021-02396-1
   PubMed Web of Science ®Google Scholar
• Gumus H. Fatigue can be objectively measured in multiple sclerosis. Arch Neuropsychiatry. 2018. doi:10.29399/npa.23396
   Google Scholar
• Billones R, Liwang JK, Butler K, Graves L, Saligan LN. Dissecting the fatigue experience: a scoping review of fatigue definitions, dimensions, and measures in non-oncologic medical conditions. Brain Behav Immun Health. 2021;15:100266. doi:10.1016/j.bbih.2021.100266
   PubMedGoogle Scholar
• Tur C. Fatigue management in multiple sclerosis. Curr Treat Options Neurol. 2016;18(6):26. doi:10.1007/s11940-016-0411-8
   PubMed Web of Science ®Google Scholar
• Patejdl R, Penner IK, Noack TK, Zettl UK. Multiple sclerosis and fatigue: a review on the contribution of inflammation and immune-mediated neurodegeneration. Autoimmun Rev. 2016;15(3):210–220. doi:10.1016/j.autrev.2015.11.005
   PubMed Web of Science ®Google Scholar
• Stampanoni Bassi M, Iezzi E, Landi D, et al. Delayed treatment of MS is associated with high CSF levels of IL-6 and IL-8 and worse future disease course. J Neurol. 2018;265(11):2540–2547. doi:10.1007/s00415-018-8994-5
   PubMed Web of Science ®Google Scholar
• Dantzer R, Kelley KW. Twenty years of research on cytokine-induced sickness behavior. Brain Behav Immun. 2007;21(2):153–160. doi:10.1016/j.bbi.2006.09.006
   PubMed Web of Science ®Google Scholar
• Capuron L. Neurobehavioral effects of interferon-α in cancer patients phenomenology and paroxetine responsiveness of symptom dimensions. Neuropsychopharmacology. 2002;26(5):643–652. doi:10.1016/S0893-133X(01)00407-9
   PubMed Web of Science ®Google Scholar
• Heesen C. Fatigue in multiple sclerosis: an example of cytokine mediated sickness behaviour? J Neurol Neurosurg Psychiatry. 2006;77(1):34–39. doi:10.1136/jnnp.2005.065805
   PubMed Web of Science ®Google Scholar
• Capuron L, Schroecksnadel S, Féart C, et al. Chronic low-grade inflammation in elderly persons is associated with altered tryptophan and tyrosine metabolism: role in neuropsychiatric symptoms. Biol Psychiatry. 2011;70(2):175–182. doi:10.1016/j.biopsych.2010.12.006
   PubMed Web of Science ®Google Scholar
• Pace TWW, Miller AH. Cytokines and glucocorticoid receptor signaling: relevance to major depression. Ann N Y Acad Sci. 2009;1179(1):86–105. doi:10.1111/j.1749-6632.2009.04984.x
   PubMedGoogle Scholar
• Goehler LE, Gaykema RPA, Hansen MK, Anderson K, Maier SF, Watkins LR. Vagal immune-to-brain communication: a visceral chemosensory pathway. Auton Neurosci. 2000;85(1–3):49–59. doi:10.1016/S1566-0702(00)00219-8
   PubMed Web of Science ®Google Scholar
• Critchley HD, Harrison NA. Visceral Influences on Brain and Behavior. Neuron. 2013;77(4):624–638. doi:10.1016/j.neuron.2013.02.008
   PubMed Web of Science ®Google Scholar
• Bonvalet M, Ollila HM, Ambati A, Mignot E. Autoimmunity in narcolepsy. Curr Opin Pulm Med. 2017;23(6):522–529. doi:10.1097/MCP.0000000000000426
   PubMed Web of Science ®Google Scholar
• Grossberg AJ, Zhu X, Leinninger GM, et al. Inflammation-induced lethargy is mediated by suppression of orexin neuron activity. J Neurosci. 2011;31(31):11376–11386. doi:10.1523/JNEUROSCI.2311-11.2011
   PubMed Web of Science ®Google Scholar
• Papuć E, Zbigniew S, Paweł G, Konrad R. CSF hypocretin-1 concentrations correlate with the level of fatigue in multiple sclerosis patients. Neurosci Lett. 2010;474(1):9–12. doi:10.1016/j.neulet.2010.02.062
   PubMed Web of Science ®Google Scholar
• Constantinescu CS, Niepel G, Patterson M, et al. Orexin A (hypocretin-1) levels are not reduced while cocaine/amphetamine regulated transcript levels are increased in the cerebrospinal fluid of patients with multiple sclerosis: no correlation with fatigue and sleepiness. J Neurol Sci. 2011;307(1–2):127–131. doi:10.1016/j.jns.2011.04.024
   PubMed Web of Science ®Google Scholar
• Cleare AJ. The neuroendocrinology of chronic fatigue syndrome. Endocr Rev. 2003;24(2):236–252. doi:10.1210/er.2002-0014
   PubMed Web of Science ®Google Scholar
• Chen CCG, Parker CR. Adrenal androgens and the immune system. Semin Reprod Med. 2004;22(04):369–377. doi:10.1055/s-2004-861553
   PubMedGoogle Scholar
• Schumann EM, Kümpfel T, Then Bergh F, Trenkwalder C, Holsboer F, Auer DP. Activity of the hypothalamic–pituitary–adrenal axis in multiple sclerosis: correlations with gadolinium‐enhancing lesions and ventricular volume. Ann Neurol. 2002;51(6):763–767. doi:10.1002/ana.10187
   PubMed Web of Science ®Google Scholar
• Versteeg GA, Ten Klooster PM, Van De Laar MAFJ. Fatigue is associated with disease activity in some, but not all, patients living with rheumatoid arthritis: disentangling “between-person” and “within-person” associations. BMC Rheumatol. 2022;6(1):3. doi:10.1186/s41927-021-00230-2
   PubMedGoogle Scholar
• Tanriverdi F, Karaca Z, Unluhizarci K, Kelestimur F. The hypothalamo–pituitary–adrenal axis in chronic fatigue syndrome and fibromyalgia syndrome. Stress. 2007;10(1):13–25. doi:10.1080/10253890601130823
   PubMed Web of Science ®Google Scholar
• Rashad NM, Amer MG, Reda Ashour WM, Hassanin HM. The pattern of thyroiditis in multiple sclerosis: a cross-sectional study in a tertiary care hospital in Egypt. Egypt J Intern Med. 2020;32(1):17. doi:10.1186/s43162-020-00017-w
   PubMedGoogle Scholar
• Niederwieser G, Buchinger W, Bonelli RM, et al. Prevalence of autoimmune thyroiditis and non-immune thyroid disease in multiple sclerosis. J Neurol. 2003;250(6):672–675. doi:10.1007/s00415-003-1053-9
   PubMed Web of Science ®Google Scholar
• Hollenbach JA, Oksenberg JR. The immunogenetics of multiple sclerosis: a comprehensive review. J Autoimmun. 2015;64:13–25. doi:10.1016/j.jaut.2015.06.010
   PubMed Web of Science ®Google Scholar
• Durelli L, Ferrero B, Oggero A, et al. Thyroid function and autoimmunity during interferon β-1b treatment: a multicenter prospective study. J Clin Endocrinol Metab. 2001;86(8):3525–3532. doi:10.1210/jcem.86.8.7721
   PubMed Web of Science ®Google Scholar
• Thompson AJ, Banwell B, Barkhof F, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018;17(2):162–173. doi:10.1016/S1474-4422(17)30470-2
   PubMed Web of Science ®Google Scholar
• Rocca MA, Parisi L, Pagani E, et al. Regional but not global brain damage contributes to fatigue in multiple sclerosis. Radiology. 2014;273(2):511–520. doi:10.1148/radiol.14140417
   PubMed Web of Science ®Google Scholar
• Marrie RA, Fisher E, Miller DM, Lee JC, Rudick RA. Association of fatigue and brain atrophy in multiple sclerosis. J Neurol Sci. 2005;228(2):161–166. doi:10.1016/j.jns.2004.11.046
   PubMed Web of Science ®Google Scholar
• Bester M, Lazar M, Petracca M, et al. Tract-specific white matter correlates of fatigue and cognitive impairment in benign multiple sclerosis. J Neurol Sci. 2013;330(1–2):61–66. doi:10.1016/j.jns.2013.04.005
   PubMed Web of Science ®Google Scholar
• Nourbakhsh B, Azevedo C, Nunan-Saah J, et al. Longitudinal associations between brain structural changes and fatigue in early MS. Mult Scler Relat Disord. 2016;5:29–33. doi:10.1016/j.msard.2015.10.006
   PubMed Web of Science ®Google Scholar
• Compston A. From The Archives. Brain. 2011;134(7):1872–1876. doi:10.1093/brain/awr150
   Google Scholar
• Snooks SJ, Swash M. Motor conduction velocity in the human spinal cord: slowed conduction in multiple sclerosis and radiation myelopathy. J Neurol Neurosurg Psychiatry. 1985;48(11):1135–1139. doi:10.1136/jnnp.48.11.1135
   PubMed Web of Science ®Google Scholar
• Broicher SD, Filli L, Geisseler O, et al. Positive effects of fampridine on cognition, fatigue and depression in patients with multiple sclerosis over 2 years. J Neurol. 2018;265(5):1016–1025. doi:10.1007/s00415-018-8796-9
   PubMed Web of Science ®Google Scholar
• Hanken K, Eling P, Kastrup A, Klein J, Hildebrandt H. Integrity of hypothalamic fibers and cognitive fatigue in multiple sclerosis. Mult Scler Relat Disord. 2015;4(1):39–46. doi:10.1016/j.msard.2014.11.006
   PubMed Web of Science ®Google Scholar
• Genova HM, Rajagopalan V, DeLuca J, et al. Examination of cognitive fatigue in multiple sclerosis using functional magnetic resonance imaging and diffusion tensor imaging. PLoS One. 2013;8(11):e78811. doi:10.1371/journal.pone.0078811
   PubMed Web of Science ®Google Scholar
• Calabrese M, Favaretto A, Martini V, Gallo P. Grey matter lesions in MS: from histology to clinical implications. Prion. 2013;7(1):20–27. doi:10.4161/pri.22580
   PubMed Web of Science ®Google Scholar
• Haider L, Zrzavy T, Hametner S, et al. The topography of demyelination and neurodegeneration in the multiple sclerosis brain. Brain. 2016;139(3):807–815. doi:10.1093/brain/awv398
   PubMed Web of Science ®Google Scholar
• Bo L, Geurts JJG, Mork SJ, Valk P. Grey matter pathology in multiple sclerosis. Acta Neurol Scand. 2006;113(s183):48–50. doi:10.1111/j.1600-0404.2006.00615.x
   Google Scholar
• Huang J, Li M, Li Q, et al. Altered functional connectivity in white and gray matter in patients with multiple sclerosis. Front Hum Neurosci. 2020;14:563048. doi:10.3389/fnhum.2020.563048
   PubMed Web of Science ®Google Scholar
• Soares JM, Conde R, Magalhães R, et al. Alterations in functional connectivity are associated with white matter lesions and information processing efficiency in multiple sclerosis. Brain Imaging Behav. 2021;15(1):375–388. doi:10.1007/s11682-020-00264-z
   PubMed Web of Science ®Google Scholar
• Burfeind KG, Yadav V, Marks DL. Hypothalamic dysfunction and multiple sclerosis: implications for fatigue and weight dysregulation. Curr Neurol Neurosci Rep. 2016;16(11):98. doi:10.1007/s11910-016-0700-3
   PubMed Web of Science ®Google Scholar
• Pallais J, Kotz C, Stanojlovic M. Orexin/hypocretinin in multiple sclerosis and experimental autoimmune encephalomyelitis. Neural Regen Res. 2020;15(6):1039. doi:10.4103/1673-5374.270310
   PubMed Web of Science ®Google Scholar
• Flachenecker P, Rufer A, Bihler I, et al. Fatigue in MS is related to sympathetic vasomotor dysfunction. Neurology. 2003;61(6):851–853. doi:10.1212/01.WNL.0000080365.95436.B8
   PubMed Web of Science ®Google Scholar
• Kantorová E, Poláček H, Bittšanský M, et al. Hypothalamic damage in multiple sclerosis correlates with disease activity, disability, depression, and fatigue. Neurol Res. 2017;39(4):323–330. doi:10.1080/01616412.2016.1275460
   PubMed Web of Science ®Google Scholar
• Filippi M, Rocca MA, Colombo B, et al. Functional magnetic resonance imaging correlates of fatigue in multiple sclerosis. NeuroImage. 2002;15(3):559–567. doi:10.1006/nimg.2001.1011
   PubMed Web of Science ®Google Scholar
• Tahedl M, Levine SM, Greenlee MW, Weissert R, Schwarzbach JV. Functional connectivity in multiple sclerosis: recent findings and future directions. Front Neurol. 2018;9:828. doi:10.3389/fneur.2018.00828
   PubMed Web of Science ®Google Scholar
• Gu Q. Neuromodulatory transmitter systems in the cortex and their role in cortical plasticity. Neuroscience. 2002;111(4):815–835. doi:10.1016/S0306-4522(02)00026-X
   PubMed Web of Science ®Google Scholar
• Schoonheim MM, Meijer KA, Geurts JJG. Network collapse and cognitive impairment in multiple sclerosis. Front Neurol. 2015;6. doi:10.3389/fneur.2015.00082
   PubMed Web of Science ®Google Scholar
• Flachenecker P, Kümpfel T, Kallmann B, et al. Fatigue in multiple sclerosis: a comparison of different rating scales and correlation to clinical parameters. Mult Scler J. 2002;8(6):523–526. doi:10.1191/1352458502ms839oa
   PubMed Web of Science ®Google Scholar
• Schürks M, Bussfeld P. Multiple sclerosis and restless legs syndrome: a systematic review and meta-analysis. Eur J Neurol. 2013;20(4):605–615. doi:10.1111/j.1468-1331.2012.03873.x
   PubMed Web of Science ®Google Scholar
• Guo S, Huang J, Jiang H, et al. Restless legs syndrome: from pathophysiology to clinical diagnosis and management. Front Aging Neurosci. 2017;9:171. doi:10.3389/fnagi.2017.00171
   PubMed Web of Science ®Google Scholar
• Manconi M, Rocca MA, Ferini-Strambi L, et al. Restless legs syndrome is a common finding in multiple sclerosis and correlates with cervical cord damage. Mult Scler J. 2008;14(1):86–93. doi:10.1177/1352458507080734
   PubMedGoogle Scholar
• Zhu XY, Wu TT, Wang HM, et al. Correlates of nonanemic iron deficiency in restless legs syndrome. Front Neurol. 2020;11:298. doi:10.3389/fneur.2020.00298
   PubMed Web of Science ®Google Scholar
• Lin M, Krishnan AV, Eckert DJ. Central sleep apnea in multiple sclerosis: a pilot study. Sleep Breath. 2017;21(3):691–696. doi:10.1007/s11325-016-1442-9
   PubMed Web of Science ®Google Scholar
• Kaynak H, Altintaş A, Kaynak D, et al. Fatigue and sleep disturbance in multiple sclerosis. Eur J Neurol. 2006;13(12):1333–1339. doi:10.1111/j.1468-1331.2006.01499.x
   PubMed Web of Science ®Google Scholar
• Braley TJ, Kratz AL, Kaplish N, Chervin RD. Sleep and cognitive function in multiple sclerosis. Sleep. 2016;39(8):1525–1533. doi:10.5665/sleep.6012
   PubMed Web of Science ®Google Scholar
• Russell RD, Langer-Gould A, Gonzales EG, et al. Obesity, dieting, and multiple sclerosis. Mult Scler Relat Disord. 2020;39:101889. doi:10.1016/j.msard.2019.101889
   PubMed Web of Science ®Google Scholar
• Abdel Salam OA, Ghonimi NAM, Ismail MH. Risk of obstructive sleep apnea in multiple sclerosis: frequency, clinical and radiological correlates. Mult Scler Relat Disord. 2019;28:184–188. doi:10.1016/j.msard.2018.12.015
   PubMed Web of Science ®Google Scholar
• Eckert DJ, Malhotra A. Pathophysiology of adult obstructive sleep apnea. Proc Am Thorac Soc. 2008;5(2):144–153. doi:10.1513/pats.200707-114MG
   PubMedGoogle Scholar
• Hensen HA, Krishnan AV, Eckert DJ. Sleep-disordered breathing in people with multiple sclerosis: prevalence, pathophysiological mechanisms, and disease consequences. Front Neurol. 2018;8:740. doi:10.3389/fneur.2017.00740
   PubMed Web of Science ®Google Scholar
• Braley TJ, Segal BM, Chervin RD. Sleep-disordered breathing in multiple sclerosis. Neurology. 2012;79(9):929–936. doi:10.1212/WNL.0b013e318266fa9d
   PubMed Web of Science ®Google Scholar
• Braley TJ, Segal BM, Chervin RD. Obstructive sleep apnea is an under-recognized and consequential morbidity in multiple sclerosis. J Clin Sleep Med. 2014;10(06):709–710. doi:10.5664/jcsm.3820
   PubMedGoogle Scholar
• Boeschoten RE, Braamse AMJ, Beekman ATF, et al. Prevalence of depression and anxiety in Multiple Sclerosis: a systematic review and meta-analysis. J Neurol Sci. 2017;372:331–341. doi:10.1016/j.jns.2016.11.067
   PubMed Web of Science ®Google Scholar
• Patrick E, Christodoulou C, Krupp L; On behalf of the New York State MS Consortium. Longitudinal correlates of fatigue in multiple sclerosis. Mult Scler J. 2009;15(2):258–261. doi:10.1177/1352458508097466
   PubMed Web of Science ®Google Scholar
• De Mendonça FMR, De Mendonça GPRR, Souza LC, et al. Benzodiazepines and sleep architecture: a systematic review. CNS Neurol Disord Drug Targets. 2023;22(2):172–179. doi:10.2174/1871527320666210618103344
   PubMed Web of Science ®Google Scholar
• Seixas D, Foley P, Palace J, Lima D, Ramos I, Tracey I. Pain in multiple sclerosis: a systematic review of neuroimaging studies. NeuroImage Clin. 2014;5:322–331. doi:10.1016/j.nicl.2014.06.014
   PubMed Web of Science ®Google Scholar
• Metz LM. The effect of immunomodulatory treatment on multiple sclerosis fatigue. J Neurol Neurosurg Psychiatry. 2004;75(7):1045–1047. doi:10.1136/jnnp.2002.007724
   PubMed Web of Science ®Google Scholar
• Svenningsson A, Falk E, Celius EG, et al. Natalizumab treatment reduces fatigue in multiple sclerosis. results from the TYNERGY trial; a study in the real life setting. PLoS One. 2013;8(3):e58643. doi:10.1371/journal.pone.0058643
   PubMed Web of Science ®Google Scholar
• DeLuca J, Genova HM, Capili EJ, Wylie GR. Functional neuroimaging of fatigue. Phys Med Rehabil Clin N Am. 2009;20(2):325–337. doi:10.1016/j.pmr.2008.12.007
   PubMed Web of Science ®Google Scholar
• Dittner AJ, Wessely SC, Brown RG. The assessment of fatigue. J Psychosom Res. 2004;56(2):157–170. doi:10.1016/S0022-3999(03)00371-4
   PubMed Web of Science ®Google Scholar
• Braley TJ, Chervin RD. Fatigue in multiple sclerosis: mechanisms, evaluation, and treatment. Sleep. 2010;33(8):1061–1067. doi:10.1093/sleep/33.8.1061
   PubMed Web of Science ®Google Scholar
• Mills RJ, Young CA, Pallant JF, Tennant A. Rasch analysis of the Modified Fatigue Impact Scale (MFIS) in multiple sclerosis. J Neurol Neurosurg Psychiatry. 2010;81(9):1049–1051. doi:10.1136/jnnp.2008.151340
   PubMed Web of Science ®Google Scholar
• Larson RD. Psychometric properties of the Modified Fatigue Impact Scale. Int J MS Care. 2013;15(1):15–20. doi:10.7224/1537-2073.2012-019
   PubMedGoogle Scholar
• Rosti‐Otajärvi E, Hämäläinen P, Wiksten A, Hakkarainen T, Ruutiainen J. Validity and reliability of the Fatigue Severity Scale in Finnish multiple sclerosis patients. Brain Behav. 2017;7(7):e00743. doi:10.1002/brb3.743
   PubMed Web of Science ®Google Scholar
• Valko PO, Bassetti CL, Bloch KE, Held U, Baumann CR. Validation of the Fatigue Severity Scale in a Swiss Cohort. Sleep. 2008;31(11):1601–1607. doi:10.1093/sleep/31.11.1601
   PubMed Web of Science ®Google Scholar
• Wearden AJ, Dowrick C, Chew-Graham C, et al. Nurse led, home based self help treatment for patients in primary care with chronic fatigue syndrome: randomised controlled trial. BMJ. 2010;340(apr22 3):c1777. doi:10.1136/bmj.c1777
   PubMedGoogle Scholar
• Chilcot J, Norton S, Kelly ME, Moss-Morris R. The Chalder Fatigue Questionnaire is a valid and reliable measure of perceived fatigue severity in multiple sclerosis. Mult Scler J. 2016;22(5):677–684. doi:10.1177/1352458515598019
   PubMed Web of Science ®Google Scholar
• Stouten B. Identification of ambiguities in the 1994 chronic fatigue syndrome research case definition and recommendations for resolution. BMC Health Serv Res. 2005;5(1):37. doi:10.1186/1472-6963-5-37
   PubMedGoogle Scholar
• Arm J, Ribbons K, Lechner-Scott J, Ramadan S. Evaluation of MS related central fatigue using MR neuroimaging methods: scoping review. J Neurol Sci. 2019;400:52–71. doi:10.1016/j.jns.2019.03.007
   PubMed Web of Science ®Google Scholar
• Gobbi C, Rocca M, Riccitelli G, et al. Influence of the topography of brain damage on depression and fatigue in patients with multiple sclerosis. Mult Scler J. 2014;20(2):192–201. doi:10.1177/1352458513493684
   PubMed Web of Science ®Google Scholar
• Gobbi C, Rocca M, Pagani E, et al. Forceps minor damage and co-occurrence of depression and fatigue in multiple sclerosis. Mult Scler J. 2014;20(12):1633–1640. doi:10.1177/1352458514530022
   PubMed Web of Science ®Google Scholar
• Hanken K, Eling P, Hildebrandt H. The representation of inflammatory signals in the brain-a model for subjective fatigue in multiple sclerosis. Front Neurol. 2014;5. doi:10.3389/fneur.2014.00264
   PubMed Web of Science ®Google Scholar
• Riccitelli G, Rocca MA, Forn C, Colombo B, Comi G, Filippi M. Voxelwise assessment of the regional distribution of damage in the brains of patients with multiple sclerosis and fatigue. Am J Neuroradiol. 2011;32(5):874–879. doi:10.3174/ajnr.A2412
   PubMed Web of Science ®Google Scholar
• Derache N, Grassiot B, Mézenge F, et al. Fatigue is associated with metabolic and density alterations of cortical and deep gray matter in Relapsing-Remitting-Multiple Sclerosis patients at the earlier stage of the disease: a PET/MR study. Mult Scler Relat Disord. 2013;2(4):362–369. doi:10.1016/j.msard.2013.03.005
   PubMed Web of Science ®Google Scholar
• Sander C, Eling P, Hanken K, Klein J, Kastrup A, Hildebrandt H. The impact of MS-related cognitive fatigue on future brain parenchymal loss and relapse: a 17-month follow-up study. Front Neurol. 2016;7. doi:10.3389/fneur.2016.00155
   PubMed Web of Science ®Google Scholar
• Bernitsas E, Yarraguntla K, Bao F, et al. Structural and neuronal integrity measures of fatigue severity in multiple sclerosis. Brain Sci. 2017;7(12):102. doi:10.3390/brainsci7080102
   PubMedGoogle Scholar
• DeLuca J, Genova HM, Hillary FG, Wylie G. Neural correlates of cognitive fatigue in multiple sclerosis using functional MRI. J Neurol Sci. 2008;270(1–2):28–39. doi:10.1016/j.jns.2008.01.018
   PubMed Web of Science ®Google Scholar
• Tartaglia MC, Narayanan S, Arnold DL. Mental fatigue alters the pattern and increases the volume of cerebral activation required for a motor task in multiple sclerosis patients with fatigue. Eur J Neurol. 2008;15(4):413–419. doi:10.1111/j.1468-1331.2008.02090.x
   PubMed Web of Science ®Google Scholar
• Rammohan KW. Efficacy and safety of modafinil (Provigil(R)) for the treatment of fatigue in multiple sclerosis: a two centre Phase 2 study. J Neurol Neurosurg Psychiatry. 2002;72(2):179–183. doi:10.1136/jnnp.72.2.179
   PubMed Web of Science ®Google Scholar
• Kunkel A, Fischer M, Faiss J, Dã¤hne D, Köhler W, Faiss JH. Impact of natalizumab treatment on fatigue, mood, and aspects of cognition in relapsing-remitting multiple sclerosis. Front Neurol. 2015;6. doi:10.3389/fneur.2015.00097
   PubMed Web of Science ®Google Scholar
• O’Connor P, Wolinsky JS, Confavreux C, et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N Engl J Med. 2011;365(14):1293–1303. doi:10.1056/NEJMoa1014656
   PubMed Web of Science ®Google Scholar
• Calkwood J, Cree B, Crayton H, et al. Impact of a switch to fingolimod versus staying on glatiramer acetate or beta interferons on patient- and physician-reported outcomes in relapsing multiple sclerosis: post hocanalyses of the EPOC trial. BMC Neurol. 2014;14(1):220. doi:10.1186/s12883-014-0220-1
   PubMedGoogle Scholar
• Veauthier C, Paul F. Therapie der Fatigue bei Multipler Sklerose: ein Behandlungsalgorithmus. Nervenarzt. 2016;87(12):1310–1321. doi:10.1007/s00115-016-0128-7
   PubMedGoogle Scholar
• Pavsic K, Pelicon K, Ledinek AH, Sega S. Short-term impact of fampridine on motor and cognitive functions, mood and quality of life among multiple sclerosis patients. Clin Neurol Neurosurg. 2015;139:35–40. doi:10.1016/j.clineuro.2015.08.023
   PubMed Web of Science ®Google Scholar
• Asano M, Finlayson ML. Meta-analysis of three different types of fatigue management interventions for people with multiple sclerosis: exercise, education, and medication. Mult Scler Int. 2014;2014:1–12. doi:10.1155/2014/798285
   Google Scholar
• Dobryakova E, Genova HM, DeLuca J, Wylie GR. The dopamine imbalance hypothesis of fatigue in multiple sclerosis and other neurological disorders. Front Neurol. 2015;6. doi:10.3389/fneur.2015.00052
   PubMed Web of Science ®Google Scholar
• National Clinical Guideline Centre (UK). Multiple sclerosis: management of multiple sclerosis in primary and secondary care. London: National Institute for Health and Care Excellence (UK). NICE Clinical Guidelines, No. 186; 2014. Available from: https://www.ncbi.nlm.nih.gov/books/NBK248064/. Accessed November 9, 2023.
   Google Scholar
• Yang -T-T, Wang L, Deng X-Y, Yu G. Pharmacological treatments for fatigue in patients with multiple sclerosis: a systematic review and meta-analysis. J Neurol Sci. 2017;380:256–261. doi:10.1016/j.jns.2017.07.042
   PubMed Web of Science ®Google Scholar
• Lange R, Volkmer M, Heesen C, Liepert J. Modafinil effects in multiple sclerosis patients with fatigue. J Neurol. 2009;256(4):645–650. doi:10.1007/s00415-009-0152-7
   PubMed Web of Science ®Google Scholar
• Möller F, Poettgen J, Broemel F, Neuhaus A, Daumer M, Heesen C. HAGIL (Hamburg Vigil Study): a randomized placebo-controlled double-blind study with modafinil for treatment of fatigue in patients with multiple sclerosis. Mult Scler J. 2011;17(8):1002–1009. doi:10.1177/1352458511402410
   PubMed Web of Science ®Google Scholar
• Garrett M, Hogan N, Larkin A, Saunders J, Jakeman P, Coote S. Exercise in the community for people with minimal gait impairment due to MS: an assessor-blind randomized controlled trial. Mult Scler J. 2013;19(6):782–789. doi:10.1177/1352458512461966
   PubMed Web of Science ®Google Scholar
• Mulero P, Almansa R, Neri MJ, et al. Improvement of fatigue in multiple sclerosis by physical exercise is associated to modulation of systemic interferon response. J Neuroimmunol. 2015;280:8–11. doi:10.1016/j.jneuroim.2015.01.011
   PubMed Web of Science ®Google Scholar
• Hourihan SJ. Managing fatigue in adults with multiple sclerosis. Nurs Stand. 2015;29(43):51–58. doi:10.7748/ns.29.43.51.e9654
   PubMedGoogle Scholar
• Hebert JR, Corboy JR, Manago MM, Schenkman M. Effects of vestibular rehabilitation on multiple sclerosis–related fatigue and upright postural control: a randomized controlled trial. Phys Ther. 2011;91(8):1166–1183. doi:10.2522/ptj.20100399
   PubMed Web of Science ®Google Scholar